In 2026, sales are expected to grow by a high single-digit percentage at CER. Business EPS at CER is expected to grow slightly faster than sales, delivering profitable growth. Sanofi (SNY) intends to execute a share buyback program in 2026 of EUR 1B.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi: De‑Risked Earnings and Robust Medium‑Term Growth Overlooked by Discounted Valuation
- Sanofi Advances PCV21 Vaccine Trial in Sickle Cell Children, Targeting an Edge in Pneumococcal Protection
- Regeneron price target raised to $916 from $911 at Bernstein
- Sanofi initiated with a Neutral at Citi
- Sanofi SA (SNY) Q4 Earnings Cheat Sheet